Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Xlife Sciences Ltd. ( (CH:XLS) ).
VERAXA Biotech AG, a portfolio company of Zurich-based incubator Xlife Sciences AG, develops antibody-drug conjugates and other antibody-based cancer therapies built on scientific discoveries from EMBL, with the goal of rapidly advancing these candidates into and through clinical development. Xlife Sciences, listed on SIX, focuses on nurturing such platforms toward the capital markets, underscoring its strategy of turning early-stage life science innovation into investable companies.
Shareholders of VERAXA Biotech AG have approved by 99.57% the three-way absorption merger with Veraxa Biotech Holding AG and U.S.-listed Voyager Acquisition Corp., clearing the way for VERAXA to list on Nasdaq under the ticker “VRXA” once Voyager investors sign off on 12 March 2026. The current management led by CEO Dr. Christoph Antz will remain in place, and Xlife Sciences says the deal validates its model of guiding high-potential oncology platforms to global capital markets, potentially strengthening VERAXA’s funding base and international profile.
More about Xlife Sciences Ltd.
Xlife Sciences AG is a Swiss life sciences incubator and accelerator that commercializes research projects from universities and institutes, aiming to address unmet medical needs and bridge the gap between R&D and healthcare markets. Its portfolio spans technology platforms, biotechnology and therapies, medical technology, and AI-driven digital health solutions, with stakes in developing companies such as oncology specialist VERAXA Biotech AG.
Average Trading Volume: 7,481
Technical Sentiment Signal: Hold
Current Market Cap: CHF129.8M
For detailed information about XLS stock, go to TipRanks’ Stock Analysis page.